GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Capex-to-Operating-Cash-Flow

CG Oncology (CG Oncology) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

CG Oncology's Capital Expenditure for the three months ended in Mar. 2024 was $-0.01 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $-26.01 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


CG Oncology Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for CG Oncology's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Capex-to-Operating-Cash-Flow Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
- - -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of CG Oncology's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, CG Oncology's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CG Oncology's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CG Oncology's Capex-to-Operating-Cash-Flow falls into.



CG Oncology Capex-to-Operating-Cash-Flow Calculation

CG Oncology's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -45.679
=N/A

CG Oncology's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.012) / -26.012
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CG Oncology  (NAS:CGON) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


CG Oncology Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CG Oncology's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CG Oncology (CG Oncology) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines